Sugi Predict

Sugi Predict / Compounds / SCHEMBL7190063

SCHEMBL7190063

SCHEMBL7190063

COc1cc(OC)c(C(=O)Pc2ccc(C)cc2C)c(OC)c1.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ CYP3A4 P08684 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ ABCG2 Q9UNQ0 2/20 0.40
▸ MEN1 O00255 3/20 0.39
▸ GAA P10253 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ AHR P35869 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7190075 0.97 MAPK1 (0.44) MAPK1SMN1; SMN2CYP3A4USP2KMT2A
SCHEMBL7187558 0.90 KMT2A (0.48) MAPK1SMN1; SMN2CYP3A4USP2KMT2A
SCHEMBL7183287 0.89 MAPK1 (0.44) MAPK1SMN1; SMN2CYP3A4USP2KMT2A
SCHEMBL7188768 0.87 CA12 (0.44) SMN1; SMN2KMT2AL3MBTL1MEN1GAA
Lithium SCHEMBL7183295 0.86 SMN1; SMN2 (0.44) MAPK1SMN1; SMN2CYP3A4USP2KMT2A
SCHEMBL7184864 0.84 CYP3A4 (0.45) MAPK1SMN1; SMN2CYP3A4USP2KMT2A
Lithium SCHEMBL7188778 0.84 CA12 (0.44) SMN1; SMN2CYP3A4KMT2AL3MBTL1MEN1
SCHEMBL7189445 0.84 KMT2A (0.43) MAPK1SMN1; SMN2CYP3A4USP2KMT2A
SCHEMBL7180950 0.83 KMT2A (0.42) MAPK1SMN1; SMN2CYP3A4USP2KMT2A
SCHEMBL7175233 0.83 KMT2A (0.42) MAPK1SMN1; SMN2CYP3A4USP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPK1 1801/4885SMN1; SMN2 2939/4885CYP3A4 1652/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPK1 2710/4885SMN1; SMN2 3105/4885CYP3A4 1881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.